It is a great pleasure and privilege to invite you to the 21st ART Vienna conference on advanced retinal therapy in the year of 2024.
Novel topics have approached on the horizon of the retina, both scientifically as well as clinically – all requiring sharing of information as well as experts’ discussion!
Our team has put together three major sessions with the topics
- Gene Therapy and Biology
- Geographic Atrophy: Diagnostic Tools
- Geographic Atrophy: Therapeutic Options
- AI-based Retinal Imaging
- Neovascular AMD in 2024
- Diabetic Macula and Retina
We have invited speakers that are excelling in moving the field ahead!
For a lively exchange of ideas and a robust understanding of contents, face-to-face encounters are essential. This year’s conference can provide this most important inter-individual exchange. Interactive discussion and debate will be strengthened by having panel discussions with participation of all speakers in small groups related to their comment topic.
With this spirit of moving the field of retina ahead in a collaborative and person-driven effort, we are very much looking forward to see and hear you on
December 7th, 2024.
Univ.-Prof. Dr. Ursula Schmidt-Erfurth
Professor and Chair
Medical University Vienna
Department of Ophthalmology and Optometry
Austrian Academy of Sciences
Full member
Van Swieten Saal, Medical University of Vienna
Van-Swieten-Gasse 1a, 1090 Vienna
This event will be approved by the Austrian Medical Chamber with 8 DFP-Points.
Registration
Programme
08:00 WELCOME
Ursula Schmidt-Erfurth
08:05 - 09:00
SESSION I: Gene Therapy and Biology
- Peter Kiraly: The pioneers in PR65: long-term experiences in gene therapy
- Christine Kay: Clinical benefit in current gene therapy trials for inherited retinal diseases
- Paul Bernstein: The Relevant Components of Macular Fluorescence
- Glenn Jaffe: Consensus Classification of Geographic Atrophy
- Paul Bernstein: Efficacy of Neurotrophic Factors in Macular Teleangiectasis
08:45 Panel Discussion
09:00 - 10:10
SESSION II: Geographic Atrophy: Diagnostic Tools
- Nancy Holekamp: Learning from "Failed" GA Trials
- Gregor Reiter: Human expert vs. AI-based evaluation of GA activity
- Amitha Domalpally: Photography and/vs. OCT in GA
- Ariadne Whitby: Imaging GA biomarkers in the real-world
- Justis Ehlers: Complete and partial loss of the ellipsoid zone as two biomarkers
- Dilraj Grewal: GA and secondary development of macular neovascularization
- Dawid Borycki: Doppler Holography for perfusion analysis in spatiotemporal OCT
09:50 Panel Discussion
10:05 Coffee Break
10:40 - 12:00
SESSION III: Geographic Atrophy: Therapeutic Options
- Paul Hahn: A comparison of complement inhibitors
- Marco Zarbin: Complement inhibition in the US clinic
- Karl Csaky: Role of functional outcomes to determine therapeutic benefits in GA treatments
- Klaudia Birner: Targeted and automated assessment of function in GA
- Maximilian Pfau: State-of-the-art in microperimetry to assess progression and therapeutic benefit in atrophic macular diseases
- Glenn Jaffe: Correlation of Ellipsoid Zone Loss and Central Visual Function
11:30 Panel Discussion
12:00 Lunch Break
13:00 - 14:30
SESSION IV: AI-based Retinal Imaging
- Michael Abramoff KEYNOTE: Regulatory rules for AI-based tools: What are the criteria?
- Julia Mai: AI-based imaging of the earliest sign in GA
- Jayashree Kalpathy-Cramer: AI for monitoring disease progression
- Ulrich Kellner: Automated macular disease monitoring in real world management
- Amitha Domalpally: From clinical biomarkers to AI-based standards
- Martin Menten: Specialist vision-language models for clinical ophthalmology
- Hrvoje Bogunovic: Foundation models: State-of-the-art and perspectives in retinal disease
14:10 Panel Discussion
14:30 Coffee Break
15:00 -16:00
SESSION V: Neovascular AMD in 2024
- Rajendra Apte: VEGP Signaling and disease
- Marco Zarbin: The most reliable path to assess durability of anti-VEGF therapy
- Nancy Holekamp: The Benefits an Challenges of Continuous Drug Delivery in nAMD
- Andrew Lotery: AMD: current thoughts on pathogenesis
- Mathew MacCumber: Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD: a DRCR Retina Network Protocol
- Sophie Frank: Impact of Fluid on functional parameters
- Rajendra Apte: Shared pathways in Neovascular and Atrophic AMD
- Daniel Barthelmes: Influence of MNV Type on therapeutical outcomes in nAMD
16:00 Panel Discussion
16:10 - 17:20
SESSION VI: Diabetic Macula and Retina
- Michael Tolentino: An overview on pathways and outcomes of DME treatments
- Catherine Creuzot-Garcher: From controlled clinical trials to real-world data: Evidence to manage DME
- Paul Hahn: Evolving Treatment Patterns in DME
- Andreas Pollreisz: Angiopoetin inhibition: Real world evidence for enhanced efficiency
- Mathew MacCumber: Symptomatic ERM In Eyes with Good Vision: The DRCR Retina Network Approach
- Michael Abramoff: Autonomous AI for the diabetic eye exam: a paradigm shift in medicine
17:00 Panel Discussion
17:20 End